Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 71, No 6 (2021)
Review paper
Published online: 2021-12-06
View PDF Download PDF file
Get Citation

Management of hepatocellular carcinoma with novel immunotherapeutic agents and prospects for the future

Katarzyna Szklener1, Michał Piwoński2, Klaudia Żak2, Julita Szarpak2, Sylwiusz Niedobylski2, Paweł Stanicki3, Sebastian Szklener4, Sławomir Mańdziuk1
DOI: 10.5603/NJO.2021.0073
·
Nowotwory. Journal of Oncology 2021;71(6):391-400.
Affiliations
  1. Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland
  2. Student Scientific Association at the Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland
  3. Student Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Lublin, Poland
  4. Department of Neurology, Medical University of Lublin, Lublin, Poland

open access

Vol 71, No 6 (2021)
Review article
Published online: 2021-12-06

Abstract

The most frequent type of primary liver cancer is hepatocellular carcinoma (HCC). Although HCC is not the most frequent cancer, it is characterized by high mortality – the 5-year survival rate is 6,9%. In recent decades there was only one molecule available in treatment (sorafenib). However, in the past few years there have been advances in treatment. Nowadays, new generation tyrosine kinase inhibitors, check point inhibitors and anti-angiogenesis drugs are available. All those studies were analyzed outcome in context of monotherapy or combined therapies. In this review we made an attempt to com­pare results from different studies. Even though, many studies are undergoing final stages of clinical trials, it seems that combined therapies should be the next step in treatment advances.

Abstract

The most frequent type of primary liver cancer is hepatocellular carcinoma (HCC). Although HCC is not the most frequent cancer, it is characterized by high mortality – the 5-year survival rate is 6,9%. In recent decades there was only one molecule available in treatment (sorafenib). However, in the past few years there have been advances in treatment. Nowadays, new generation tyrosine kinase inhibitors, check point inhibitors and anti-angiogenesis drugs are available. All those studies were analyzed outcome in context of monotherapy or combined therapies. In this review we made an attempt to com­pare results from different studies. Even though, many studies are undergoing final stages of clinical trials, it seems that combined therapies should be the next step in treatment advances.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

hepatocellular carcinoma; targeted therapy; immunotherapy

About this article
Title

Management of hepatocellular carcinoma with novel immunotherapeutic agents and prospects for the future

Journal

Nowotwory. Journal of Oncology

Issue

Vol 71, No 6 (2021)

Article type

Review paper

Pages

391-400

Published online

2021-12-06

Page views

5801

Article views/downloads

347

DOI

10.5603/NJO.2021.0073

Bibliographic record

Nowotwory. Journal of Oncology 2021;71(6):391-400.

Keywords

hepatocellular carcinoma
targeted therapy
immunotherapy

Authors

Katarzyna Szklener
Michał Piwoński
Klaudia Żak
Julita Szarpak
Sylwiusz Niedobylski
Paweł Stanicki
Sebastian Szklener
Sławomir Mańdziuk

References (85)
  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69–90.
    CrossRefPubMed
  2. Ozakyol A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J Gastrointest Cancer. 2017; 48(3): 238–240.
    CrossRefPubMed
  3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7): 2557–2576.
    CrossRefPubMed
  4. Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018; 12: 26–32.
    CrossRefPubMed
  5. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529–538.
    CrossRefPubMed
  6. Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016; 36(3): 317–324.
    CrossRefPubMed
  7. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4): 835–853.
    CrossRefPubMed
  8. Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019; 19(2): 177–189.
    CrossRefPubMed
  9. Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. Profiles Drug Subst Excip Relat Methodol. 2019; 44: 239–266.
    CrossRefPubMed
  10. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378–390.
    CrossRefPubMed
  11. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57(4): 821–829.
    CrossRefPubMed
  12. Kondo M, Morimoto M, Kobayashi S, et al. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer. 2019; 19(1): 954.
    CrossRefPubMed
  13. Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs. 2019; 79(6): 665–674.
    CrossRefPubMed
  14. Rimassa L, Wörns MA. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver Int. 2020; 40(8): 1800–1811.
    CrossRefPubMed
  15. Fung A, Tam V, Meyers D, et al. Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S). J Clin Oncol. 2019; 37(4_suppl): 422–422.
    CrossRef
  16. Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018; 19(5): 682–693.
    CrossRefPubMed
  17. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013; 31(28): 3509–3516.
    CrossRefPubMed
  18. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014; 312(1): 57–67.
    CrossRefPubMed
  19. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017; 389(10064): 56–66.
    CrossRef
  20. Grothey A, Blay JY, Pavlakis N, et al. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020; 86: 101993.
    CrossRefPubMed
  21. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013; 12(7): 1322–1331.
    CrossRefPubMed
  22. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12): 2298–2308.
    CrossRefPubMed
  23. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12): 915–925.
    CrossRefPubMed
  24. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004; 6(1): 61–73.
    CrossRefPubMed
  25. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002; 16(1): 108–110.
    CrossRefPubMed
  26. Firtina Karagonlar Z, Koc D, Iscan E, et al. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016; 107(4): 407–416.
    CrossRefPubMed
  27. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1): 54–63.
    CrossRefPubMed
  28. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28(5): 780–787.
    CrossRefPubMed
  29. Zhu AX, Park JOh, Ryoo BY, et al. REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16(7): 859–870.
    CrossRefPubMed
  30. Zhu A, Ryoo BY, Yen CJ, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study. J Clin Oncol. 2015; 33(3_suppl): 232–232.
    CrossRef
  31. Zhu AX, Kang YK, Yen CJ, et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2): 282–296.
    CrossRefPubMed
  32. Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol. 2019; 25(24): 2977–2989.
    CrossRefPubMed
  33. Ishiguro T, Sano Y, Komatsu SI, et al. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017; 9(410).
    CrossRefPubMed
  34. Takahashi Y, Ohta T, Mai M. Angiogenesis of AFP producing gastric carcinoma: correlation with frequent liver metastasis and its inhibition by anti-AFP antibody. Oncol Rep. 2004; 11(4): 809–813.
    PubMed
  35. Ghassemi S, Milone MC. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy. J Vis Exp. 2019(154).
    CrossRefPubMed
  36. Mata-Molanes JJ, Sureda González M, Valenzuela Jiménez B, et al. Cancer Immunotherapy with Cytokine-Induced Killer Cells. Target Oncol. 2017; 12(3): 289–299.
    CrossRefPubMed
  37. Bagheri Y, Barati A, Aghebati-Maleki A, et al. Current progress in cancer immunotherapy based on natural killer cells. Cell Biol Int. 2021; 45(1): 2–17.
    CrossRefPubMed
  38. Calmeiro J, Carrascal MA, Tavares AR, et al. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics. 2020; 12(2).
    CrossRefPubMed
  39. Slingluff C. The Present and Future of Peptide Vaccines for Cancer. The Cancer Journal. 2011; 17(5): 343–350.
    CrossRef
  40. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015; 15(1): 45–56.
    CrossRefPubMed
  41. Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014; 60(5): 1776–1782.
    CrossRefPubMed
  42. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011; 1217: 45–59.
    CrossRefPubMed
  43. Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017; 355(6332): 1428–1433.
    CrossRefPubMed
  44. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10(3): 727–742.
    PubMed
  45. El-Khoueiry A, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet. 2017; 389(10088): 2492–2502.
    CrossRef
  46. Bristol-Myers Squibb. A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459). Report No.: NCT02576509. https://clinicaltrials.gov/ct2/show/NCT02576509 (10.05.2021).
  47. Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018; 119(5): 538–545.
    CrossRefPubMed
  48. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020; 21(4): 571–580.
    CrossRefPubMed
  49. Jiangsu HengRui Medicine Co., Ltd. A Phase III, Multicentered, Randomized, Double-blinded, Parallel Controlled Study to Evaluate Camrelizumab (PD-1 Antibody) in Combination With FOLFOX4 Regimen Versus Placebo in Combination With FOLFOX4 Regime in First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). Report No.: NCT03605706. https://clinicaltrials.gov/ct2/show/NCT03605706 (10.05.2021).
  50. Finn RS, Ryoo BY, Merle P, et al. KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020; 38(3): 193–202.
    CrossRefPubMed
  51. Zhu AX, Finn RS, Edeline J, et al. KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7): 940–952.
    CrossRefPubMed
  52. Innovent Biologics (Suzhou) Co. Ltd. A Randomized, Open-label，Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma. (ORIENT-32). Report No.: NCT03794440. https://clinicaltrials.gov/ct2/show/NCT03794440 (10.05.2021).
  53. BeiGene. RATIONALE-301: A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma. Report No.: NCT03412773. https://clinicaltrials.gov/ct2/show/NCT03412773 (10.05.2021).
  54. Voutsadakis IA. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. Hepatobiliary Pancreat Dis Int. 2019; 18(6): 505–510.
    CrossRefPubMed
  55. Wainberg Z, Segal N, Jaeger D, et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2017; 35(15_suppl): 4071–4071.
    CrossRef
  56. Kroemer G, Zitvogel L, Krummel MF, et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182(2): 459–465.
    CrossRefPubMed
  57. Chen J, Ganguly A, Mucsi AD, et al. Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy. J Exp Med. 2017; 214(2): 327–338.
    CrossRefPubMed
  58. Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013; 59(1): 81–88.
    CrossRefPubMed
  59. AstraZeneca. A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma [Internet]. Report No.: NCT03298451. https://clinicaltrials.gov/ct2/show/NCT03298451 (10.05.2021).
  60. Novartis Pharmaceuticals. A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies. Report No.: NCT02947165. https://clinicaltrials.gov/ct2/show/NCT02947165 (10.05.2021).
  61. University of Hawaii. Phase II Study of TSR-022 in Combination With TSR-042 for the Treatment of Advanced Hepatocellular Carcinoma. Report No.: NCT03680508. https://clinicaltrials.gov/ct2/show/NCT03680508 (10.05.2021).
  62. Bristol-Myers Squibb. A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors. Report No.: NCT01968109. https://clinicaltrials.gov/ct2/show/NCT01968109 (10.05.2021).
  63. Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol. 2012; 40(1): 63–70.
    CrossRefPubMed
  64. Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010; 138(5): 1931–1942.
    CrossRefPubMed
  65. Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006; 12(23): 3716–3721.
    CrossRefPubMed
  66. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017; 66(3): 545–551.
    CrossRefPubMed
  67. Lee MS, Ryoo BY, Hsu CH, et al. GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020; 21(6): 808–820.
    CrossRefPubMed
  68. Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020; 16(15): 975–989.
    CrossRefPubMed
  69. Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020; 6(11): e204564.
    CrossRefPubMed
  70. Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer. https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer.html (01.03.2021).
  71. Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020; 137: 272–284.
    CrossRefPubMed
  72. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020; 38(26): 2960–2970.
    CrossRefPubMed
  73. Schulte N, Li M, Zhan T, et al. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. Z Gastroenterol. 2020; 58(8): 773–777.
    CrossRefPubMed
  74. Liu Z, Li X, He X, et al. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer. 2019; 19(1): 1062.
    CrossRefPubMed
  75. Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020; 38(26): 2981–2992.
    CrossRefPubMed
  76. Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(5): 711–718.
    CrossRefPubMed
  77. Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(8): 1057–1065.
    CrossRefPubMed
  78. Motzer R, Alekseev B, Rha SY, et al. CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14): 1289–1300.
    CrossRefPubMed
  79. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020; 31(8): 1030–1039.
    CrossRefPubMed
  80. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12): 1103–1115.
    CrossRefPubMed
  81. Kudo M, Motomura K, Wada Y, et al. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100). J Clin Oncol. 2019; 37(15_suppl): 4072–4072.
    CrossRef
  82. Thomas MB, Garrett-Mayer E, Anis M, et al. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology. 2018; 94(6): 329–339.
    CrossRefPubMed
  83. He L, Deng H, Lei J, et al. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. BMC Cancer. 2019; 19(1): 276.
    CrossRefPubMed
  84. Kaseb AO, Morris JS, Iwasaki M, et al. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9: 773–780.
    CrossRefPubMed
  85. Yau T, Wong H, Chan P, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs. 2012; 30(6): 2384–2390.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl